CIRUGÍA Y SUS ESPECIALIDADES
Departamento
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (7)
2024
-
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
European Journal of Cancer, Vol. 199
-
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
ESMO Open, Vol. 9, Núm. 3
2023
-
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795
-
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5118-5130
-
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology
2011
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
The Lancet, Vol. 378, Núm. 9793, pp. 771-784
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
The Lancet, Vol. 378, Núm. 9793, pp. 771-784